The group said the customer is an Italian group that provides tests across Europe for businesses such as airports.
BATM said it expects to receive further significant orders from the buyer, both near-term and in the next year.
Being delivered are PCR antigen tests, which diagnose whether someone is currently infected with the virus, and the Ampilab qPCR and Extralab instruments. The Ampilab 6 band qPCR instrument can run all standard test kits, but also advanced gene kits, such as the BATM’s newest COVID-19 antigen kit.
"The substantial interest in these solutions is growing as the pandemic prevails throughout much of the world and we head towards flu season,” BATM chief executive, Dr Zvi Marom said in a statement.
“We believe that we will receive further sizeable orders from our existing customers as well as continue to gain new customers for these products.”
In the same announcement BATM updated on the progress being made with its next generation of testing kits.
It said it has started to deliver its COVID-19 antigen kit that was upgraded to detect the spike protein, which accurately finds those with a low viral load who might unknowingly be spreading the infection.
BATM’s new multi-pathogen respiratory kit, meanwhile, is in the final validation phase and production and deliveries are expected to commence during the current quarter.
The firm also revealed that production is starting on the group's jointly-developed home test kit for flu after the device was CE certified and validated.
And it said it was making “strong progress” with a jointly-developed COVID-19 home test kit, which is at an advanced development stage.
"We are also delighted with the progress that we have made with our newly-developed tests for COVID-19, flu and other respiratory disease,” said Marom. “Thanks to our innovative diagnostic platform, we can offer a high-quality comprehensive solution to help protect public health in the current pandemic and beyond."